Section 3 of 6
Product information and disease description
301 evidence topics · 102 sources
Product description
Phase of product development
Regulatory status: Under review; NDA resubmitted September 2026 and accepted October 2026
Launch
No evidence found.
Investigational status
Orphan drug, breakthrough therapy, and priority review designations
No evidence found.
Original New Drug Application submission, filing acceptance, and PDUFA date
Complete Response Letter dated January 30, 2026
Type A meeting completed March 2026
Topline human factors and pharmacokinetic results announced August 2026
Expected review classification and timeline for the resubmission
Regulatory filings outside the United States
Citizen petitions relating to Anaphylm
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Aquestive Therapeutics
Therapeutic class: epinephrine prodrug delivered as a sublingual film
Dosage forms and strengths
PharmFilm polymer matrix
Primary packaging: pouch and carton
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Average sales price and wholesale acquisition cost
No evidence found.
Payer and pricing research before a possible launch
EpiPen 0.3 mg two-pack: national average drug acquisition cost
| Field | Quoted record |
|---|---|
| Product description | “EPIPEN 2-PAK 0.3 MG AUTO-INJCT” |
| National Drug Code | “49502050002” |
| NADAC per unit | “289.96000” |
| Corresponding generic NADAC per unit | “141.50252” |
| File date | “2025-11-12” |
Authorized generic epinephrine 0.3 mg auto-injector: national average drug acquisition cost
| Field | Quoted record |
|---|---|
| Product description | “EPINEPHRINE 0.3 MG AUTO-INJECT” |
| National Drug Code | “49502010202” |
| NADAC per unit | “141.13969” |
| File date | “2026-09-16” |
Auvi-Q 0.3 mg auto-injector: national average drug acquisition cost
| Field | Quoted record |
|---|---|
| Product description | “AUVI-Q 0.3 MG AUTO-INJECTOR” |
| National Drug Code | “60842002301” |
| NADAC per unit | “309.37573” |
| File date | “2026-09-16” |
Epinephrine nasal spray 2 mg: national average drug acquisition cost
| Field | Quoted record |
|---|---|
| National Drug Code | “82580002002” |
| NADAC per unit | “359.54780” |
| File date | “2026-09-16” |
Epinephrine nasal spray: cash price and copay support
American hospital formulary service (AHFS), or other drug classification
Anatomical Therapeutic Chemical classification of epinephrine
| ATC code | Name | DDD | Unit | Route |
|---|---|---|---|---|
| “C01CA24” | “epinephrine” | “0.5” | “mg” | “P” |
Indication
Intended population: participants weighing 30 kg or more
Pharmacology
Mechanism of action
Epinephrine actions at alpha- and beta-adrenergic receptors in anaphylaxis
Receptor subtypes: alpha-1 vasoconstriction, beta-1 cardiac stimulation, beta-2 bronchial relaxation
“Epinephrine increases cardiac output by stimulating β1-adrenergic receptors within the heart and causes vasoconstriction by the activation of α1-adrenergic receptor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although systemic IM or IV administered epinephrine binds to α- and β-adrenergic receptors nonselectively, inhaled epinephrine is delivered to the pulmonary airways that predominantly contain β2-adrenergic receptors in the bronchial smooth muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combined alpha- and beta-adrenergic effects as the basis of first-line treatment
“Through its combined α- and β-adrenergic effects, epinephrine counteracts vasodilation and increased vascular permeability, improves blood pressure and coronary perfusion, relaxes bronchial smooth muscle, and reduces mucosal edema in the upper airway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dibutepinephrine as a polymer matrix-based epinephrine prodrug
Sublingual film application and delivery of epinephrine
Prodrug formulation delivered on PharmFilm technology
AdrenaVerse platform: control of absorption and conversion rates
Conversion of the prodrug to epinephrine after administration
Rationale for a prodrug: overcoming the barrier properties of the oral mucosa
Sublingual delivery of a prodrug of epinephrine in an investigational film
Pharmacodynamics
Phase 3 pharmacodynamics: blood pressure and heart rate versus intramuscular comparators
“AQST-109 demonstrated more rapid and larger increases in blood pressure and heart rate than the comparators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RD AQST-109 had greater than dose-proportional increases in PK and PD parameters, exceeding the comparators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Integrated phase 1 pharmacodynamics: systolic and diastolic blood pressure and heart rate
Pivotal study: pharmacodynamic change at the first tracked time point
Pharmacodynamic responses relative to auto-injectors and manual intramuscular epinephrine
Blood pressure direction compared with manual intramuscular injection
Self-administration versus clinician administration: pharmacodynamic response
Pharmacodynamics under oral allergen challenge
“Pharmacodynamics were not impacted by OAC after single- and repeat-dose administration of AQST-109 vs without OAC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single- and repeat-dosing PD parameters were higher with AQST-109 after OAC vs intramuscular epinephrine injection without OAC, and were nonsignificantly higher for AQST-109 with vs without OAC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics after deliberate top-of-tongue placement
Pharmacodynamics after water of differing temperature and pH
Preclinical pharmacology: minipig exposure and prodrug half-life
Pharmacokinetics
Phase 3 pivotal study: maximum concentration and time to maximum concentration
Phase 3 pivotal study: bracketing of exposure and consistency of time to maximum concentration
“After single dose AQST-109 administration, area under the curve and maximum serum concentration met the primary end point of PK bracketing of 60 minutes, exceeding that of manual intramuscular injection, equaling EpiPen, but lower than that of Auvi-Q.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“AQST-109 had a median time-to-maximum plasma concentration of 12 minutes, exceeding that of EpiPen (20 minutes), Auvi-Q (30 minutes), and intramuscular injection (50 minutes); there was also more consistency (narrower IQR) than the comparators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single dose AQST-109 demonstrated PK exposures consistently bracketed within established levels for approved intramuscular epinephrine and autoinjectors, with a more rapid time-to-maximum plasma concentration and comparable PD responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 pivotal study: repeat dosing
Integrated phase 1 analysis: exposure and time to maximum concentration versus injected epinephrine
“AQST-109 yielded comparable epinephrine PK and exposure to both manual intramuscular injections and epinephrine autoinjectors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to maximum concentration (Tmax) for AQST-109 was 15 minutes, compared with EpiPen (10 minutes), generic EpiPen (15 minutes), Auvi-Q (30 minutes), and manual intramuscular injection (50 minutes).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“AQST-109 delivered epinephrine with PK and PD results within the bracketed range of approved intramuscular products.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose escalation and dose proportionality in the phase 1 study
Confirmatory pharmacokinetic study: self-administration versus clinician administration and manual intramuscular epinephrine
Confirmatory pharmacokinetic study: design and self-administration accuracy
Earlier self-administration pharmacokinetic study: time to maximum concentration
Effect of swallowing the film whole with water
Effect of water temperature and pH in the mouth
Effect of tongue position: deliberate top-of-tongue and roof-of-mouth placement
Effect of hold time before swallowing saliva
“Furthermore, the PK‐PD data were compared according to three different methods of administration in 24 healthy adult volunteers: keeping the film 4 min under the tongue before swallowing saliva, 2 min under the tongue before swallowing saliva and keeping the film under the tongue while swallowing saliva at the same time. The data were similar in the three situations without a benefit for keeping the film beyond 2 min [55].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral allergy syndrome: pharmacokinetics with and without oral allergen challenge
“During screening with OAC, 94.4% of the 36 patients experienced moderate or severe oral symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“AQST-109 PK values were similar with or without OAC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“AQST-109 PK and PD are not diminished with oral symptoms and changes, supporting reliable absorption in allergic reactions in such contexts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral allergy syndrome study: consistency of the absorption profile
Pediatric pharmacokinetics in participants aged 7 to 17 years
Comparison with nasal and oral alternatives to injected epinephrine
“Data from these studies indicate promising pharmacokinetic results comparable to those of the standard of outpatient emergency care (0.3-mg EAI) and syringe and needle IM epinephrine administration. Several products have shown maximum plasma concentration values higher than those of the 0.3-mg EAI and manual IM injection, although it remains unclear whether this has clinical relevancy in patient outcomes. Generally, these modalities show comparable time to maximum concentrations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Epinephrine class: absence of contraindications in approved labeling
Epinephrine class: common systemic adverse reactions
Epinephrine class: postapproval adverse reactions
Epinephrine class: coexisting conditions that increase the risk of adverse reactions
Anaphylm clinical program: overall tolerability
Phase 3 pivotal study: serious adverse events
Oral allergy syndrome study: treatment-emergent adverse events
Oral allergy syndrome study: severity and resolution of adverse events
Confirmatory pharmacokinetic study: tolerability and film retention
Reported frequency of oral and sublingual swelling in the oral allergy syndrome study
Proposed labeling published by a regulator
Not applicable.
Special populations
Pediatric participants aged 7 to 17 years weighing at least 30 kilograms
Pediatric study design and completion
Epinephrine class: pregnancy
Epinephrine class: organ contributions to elimination
Hepatic and renal impairment: dedicated studies of dibutepinephrine
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on dibutepinephrine
Epinephrine class: drugs increasing the risk of cardiac arrhythmias
Epinephrine class: drugs potentiating the effects of epinephrine
Epinephrine class: drugs antagonizing the effects of epinephrine
Interaction studies specific to dibutepinephrine
No evidence found.
Effects of dibutepinephrine on other drugs
Effect of dibutepinephrine on the pharmacokinetics of other drugs
No evidence found.
Dosing and administration
Dosage
Prodrug dose expressed as epinephrine equivalent
Single and repeat dosing across the clinical program
Repeat dosing evaluated in the phase 3 study
“In this 2-part, phase 3, open-label study, participants received single dose and RD of AQST-109 and epinephrine via manual syringe, EpiPen, or Auvi-Q autoinjector on different days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RD AQST-109 had greater than dose-proportional increases in PK and PD parameters, exceeding the comparators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pediatric dosing by age and weight in the completed pediatric study
Administration
Revised packaging, pouch opening, and instructions for use
Median pouch-opening time and administration errors in the human factors validation study
Self-administration without protocol-defined use errors
Access and distribution
Allergist-first launch strategy
Planned sales force size and prescriber targeting
Out-licensing of commercialization rights outside the United States
Co-prescribed/Concomitant therapies
Additional epinephrine doses in anaphylaxis management
Repeat-dose exposure in the clinical development program
Concomitant antihistamines or corticosteroids
No evidence found.
Effect of dibutepinephrine on quality measures
Product-specific effect on quality measures
No evidence found.
Product comparison
Comparator epinephrine products marketed in the United States
Route, portability, and needle-free status versus auto-injectors
Comparison with epinephrine nasal spray: no head-to-head data
Preference survey comparing the film with a nasal spray device
Place of product in therapy
Disease description
Definition and etiology
Consensus definition of anaphylaxis
“Anaphylaxis is a serious allergic (hypersensitivity) reaction that can progress rapidly and may cause death. It may involve the skin/mucosa (includes lip/tongue), respiratory (lungs, breathing), cardiovascular (heart, blood pressure), and/or gastrointestinal (stomach/gut) systems. Life-threatening anaphylaxis is characterized by respiratory and/or cardiovascular involvement and may occur without skin/mucosa involvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anaphylaxis as a type I, IgE-mediated hypersensitivity reaction
“Anaphylaxis is classically described as a type 1 hypersensitivity reaction driven by IgE-mediated release of histamine and other mediators from effector cells (such as mast cells) after allergen exposure. Non-IgE-mediated anaphylaxis is also well described, particularly to some drugs and certain types of exercise-induced anaphylaxis; symptoms/signs are indistinguishable from IgE-mediated anaphylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type I allergic pathway as the primary mechanism of anaphylaxis
World Allergy Organization definition of anaphylaxis and severe anaphylaxis
“Anaphylaxis is a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death. Severe anaphylaxis is characterized by potentially life-threatening compromise in airway, breathing and/or the circulation, and may occur without typical skin features or circulatory shock being present.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunologic and non-immunologic mechanisms of hypersensitivity
Most frequent elicitor groups worldwide
“The most frequent elicitor groups worldwide are food, insect venom, and drugs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elicitor groups other than the above mentioned are natural rubber latex, seminal fluid, radiocontrast media, medical dyes, and a variety of substances which are administered to patients in the perioperative setting (eg, suxamethonium, rocuronium, thiopental, propofol, opioids, protamine, chlorhexidine, plasma expanders)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food and drug elicitors by age and region
“The most frequent elicitors of food-induced anaphylaxis in children are hen's egg (in infants and pre-school children), cow's milk, wheat, and peanut.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Peanut and tree nuts are dominating elicitors of food-induced anaphylaxis in adults in North America and Australia; whereas, shellfish is a frequent elicitor of food-induced anaphylaxis in Asia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug-induced anaphylaxis is most frequently triggered by antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), again with age and geographical variations worldwide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of anaphylaxis attributed to food, stings, and medications
“The most common causes for anaphylaxis across all age groups include food (33%), stings (19%) and medications (14%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children, food allergies account for most cases of anaphylaxis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Triggers of anaphylaxis emergency department visits in older versus younger United States adults
“Compared to younger adults, visits among older adults were more likely to involve anaphylaxis from medications (34.0% vs 21.3%; odds ratio (OR) 1.85, 95% confidence interval (CI) 1.34, 2.55) and intravenous (IV) contrast (13.2% vs 5.6%; OR 2.50, 95% CI 1.55, 4.04).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Idiopathic anaphylaxis as a proportion of cases
Cofactors that increase the severity of a reaction
Epidemiology
Incidence of Type I allergic reactions including anaphylaxis
Worldwide incidence of anaphylaxis and the range reported in children
“Recent publications show a global incidence of anaphylaxis between 50 and 112 episodes per 100 000 person-years while the estimated lifetime prevalence is 0.3–5.1%, variations depending on the definitions used, study methodology, and geographical areas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to a recent systematic review, in children, the incidence of anaphylaxis ranged from 1 to 761 per 100 000 person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled population-based incidence of all-cause anaphylaxis and its annual rate of increase
“The current incidence worldwide was found to be approximately 46 cases per 100,000 population per year (95% CI 21–103).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a random effects Poisson model we calculated a yearly increase of anaphylaxis incidence by 7.4% (95% CI 7.3–7.6, p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States emergency department visits for anaphylaxis among infants and toddlers, 2006 to 2015
“Among infants and toddlers, the proportion of ED visits for anaphylaxis per year increased from 20 per 100,000 visits to 50 per 100,000 visits (Ptrend <0.001). The rate of ED visits for anaphylaxis increased from 15 to 32 ED visits per 100,000 population of infants and toddlers (Ptrend <0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of hospitalization among anaphylaxis-related ED visits decreased from 19% to 6% (Ptrend <0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States emergency department visits and hospitalizations for anaphylaxis among adults aged 65 years and older, 2006 to 2014
“In 2006–2014, older adults experienced approximately 1,019,967 AAR-related ED visits; 173,844 AAR-related hospitalizations; 93,795 anaphylaxis-related ED visits; and 72,677 anaphylaxis-related hospitalizations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While AAR-related ED visit and hospitalization rates remained stable (P-trends=0.28 and 0.16, respectively), anaphylaxis-related ED visit and hospitalization rates significantly increased over time (37 visits per 100,000 population in 2006 to 51 in 2014, P-trend<0.001; 13 hospitalizations per 100,000 population in 2006 to 23 in 2014, P-trend<0.001), especially hospitalization rates for drug-related anaphylaxis (47 hospitalizations per 100,000 population in 2006 to 85 in 2014, P-trend<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trend in United States pediatric emergency department visits for anaphylaxis, 2016 to 2022
State-level and health maintenance organization estimates of pediatric anaphylaxis rates in the United States
“A study observing emergency department visits and hospital admissions in the US State of Illinois due to anaphylaxis, estimated a 29.1% annual increase of emergency department and hospital admissions among children from 6.3 per 100,000 children in 2008 to 17.2 per 100,000 children in 2012” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These 2012 estimates are substantially higher than previous estimates of 10.5 per 100,000 person/year for all-cause anaphylaxis among pediatric patients treated from 1991-1997 by a large health maintenance organization in the state of Washington.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom hospital admissions for food-induced anaphylaxis, 1998 to 2018
“Food anaphylaxis admissions increased from 1.23 to 4.04 per 100 000 population per year (from 1998 to 2018), an annual increase of 5.7% (95% confidence interval 5.5% to 5.9%, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The largest increase in hospital admissions was observed in children younger than 15 years, with an increase from 2.1 to 9.2 admissions per 100 000 population per year (an annual increase of 6.6%, 95% confidence interval 6.3% to 7.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization incidence for food-induced anaphylaxis in Spain, 2016 to 2021
“A total of 2161 hospital admissions for FIA were recorded in Spain from 2016 to 2021. The overall incidence rate was 0.77 cases per 100,000 person-years. The highest incidence was found in those aged <15 years (3.68), with lower figures among those aged 15 to 59 years (0.25) and ≥60 years (0.29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Type I allergic reactions including anaphylaxis
Lifetime prevalence of anaphylaxis in the United States
Prevalence of food allergy, epinephrine prescription, and emergency department use among United States adults
“Estimated convincing food allergy prevalence among US adults was 10.8% (95% CI, 10.4%-11.1%), although 19.0% (95% CI, 18.5%-19.5%) of adults self-reported a food allergy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common allergies were shellfish (2.9%; 95% CI, 2.7%-3.1%), milk (1.9%; 95% CI, 1.8%-2.1%), peanut (1.8%; 95% CI, 1.7%-1.9%), tree nut (1.2%; 95% CI, 1.1%-1.3%), and fin fish (0.9%; 95% CI, 0.8%-1.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regarding health care utilization, 24.0% (95% CI, 22.6%-25.4%) reported a current epinephrine prescription, and 38.3% (95% CI, 36.7%-40.0%) reported at least 1 food allergy–related lifetime emergency department visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of food allergy and epinephrine autoinjector prescription among United States children
“Overall, estimated current FA prevalence was 7.6% (95% confidence interval: 7.1%–8.1%) after excluding 4% of children whose parent-reported FA reaction history was inconsistent with immunoglobulin E–mediated FA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most prevalent allergens were peanut (2.2%), milk (1.9%), shellfish (1.3%), and tree nut (1.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, 19.0% reported ≥1 FA-related emergency department visit in the previous year and 42.0% reported ≥1 lifetime FA-related emergency department visit, whereas 40.7% had a current epinephrine autoinjector prescription.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution of food allergy across racial, ethnic, and income groups in the United States
“Food allergies affect approximately 8% of children and 11% of adults in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non-Hispanic White individuals across all ages had the lowest rate of self-reported or parent-reported food allergies (9.5% [95% CI, 9.2%-9.9%]) compared with Asian (10.5% [95% CI, 9.1%-12.0%]), Hispanic (10.6% [95% CI, 9.7%-11.5%]), and non-Hispanic Black (10.6% [95% CI, 9.8%-11.5%]) individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non-Hispanic Black individuals were most likely to report allergies to multiple foods (50.6% [95% CI, 46.1%-55.1%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of allergy to multiple foods among United States children and adults
Pooled prevalence of food allergy and food sensitization in Europe
“Pooled lifetime and point prevalence of self‐reported FA were 19.9% (95% CI 16.6–23.3) and 13.1% (95% CI 11.3–14.8), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The point prevalence of sensitization based on specific IgE (slgE) was 16.6% (95% CI 12.3–20.8), skin prick test (SPT) 5.7% (95% CI 3.9–7.4), and positive food challenge 0.8% (95% CI 0.5–0.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Hymenoptera venom anaphylaxis in a United States beneficiary population
Prevalence of documented penicillin allergy in the United States
Growth in adrenaline autoinjector prescriptions relative to hospital admissions
Natural history, survival, and mortality
Case fatality rate among United States hospitalizations and emergency department presentations
“CFRs were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall mortality rates ranged from 0.63 to 0.76 per million population (186 to 225 deaths per year, MCDD), and appeared stable in the last decade (annual percent change: –0.31%; 95% CI, –1.54% to 0.93%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anaphylaxis deaths in the United States by cause, 1999 to 2010
“There were a total of 2,458 anaphylaxis deaths in the US from 1999 to 2010. Medications were the most common cause (58.8%), followed by unspecified anaphylaxis (19.3%), venom (15.2%), and food (6.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a significant increase in fatal drug anaphylaxis over twelve years: from 0.27 (95%CI: 0.23-0.30) in 1999-2001 to 0.51 (95%CI: 0.47-0.56) per million in 2008-2010, P<0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated annual anaphylaxis deaths in the United States
Proportion of anaphylaxis presentations with a fatal outcome
“An estimated, 1% of hospitalizations and 0.1% of emergency department attendances for anaphylaxis have a fatal outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, although food-related anaphylaxis is relatively common, fatalities remain rare with a reported range of approximately 0.03 to 0.3 deaths per million person years in the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Demographic pattern of fatal venom anaphylaxis
Time from allergen exposure to cardiorespiratory arrest in fatal food-induced anaphylaxis
Predictors of fatal anaphylaxis in a systematic review of 28 studies
“Asthma, cardiovascular comorbidities, and older age (≥65 years) were frequently reported predictors of mortality. Delayed epinephrine administration defined as more than 30 min after symptom onset or failure to administer in the prehospital setting was also associated with fatal outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of triggers, FIA was described in 15 studies encompassing 1,347 patients with anaphylaxis, of which 281 (20.9%) were fatalities explicitly attributed to food exposure. Peanut was the most commonly implicated allergen, followed by cow’s milk. Venom-induced anaphylaxis was reported in five studies, involving 970 patients, among whom 181 (18.7%) experienced fatal reactions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Biphasic anaphylaxis: reported rates in registry and multicenter cohorts
“Among 9171 patients in the cohort, 435 (4.7%) experienced biphasic anaphylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2025 study from 31 North American pediatric EDs found that among 5641 children with anaphylaxis, the incidence of biphasic anaphylaxis and biphasic non-anaphylaxis was 1.5% and 4.2%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Early studies reported that up to 21% of patients might experience biphasic anaphylaxis, while other studies found lower rates of biphasic reactions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of biphasic reactions and reported range of prevalence
Risk factors for severe anaphylaxis
Pathophysiology
Sensitization and IgE binding to high-affinity receptors on mast cells and basophils
“The initial pathogenic step in the development of IgE-dependent type I allergy is sensitization, a process mediated by the uptake of allergens by antigen-presenting cells (APCs). APCs capture and process allergens, presenting fragments on their surface via MHC class II molecules, undergo maturation, and migrate to regional lymph nodes, where they present these antigens to naïve T cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the effector phase, re-exposure to the same allergen cross-links the IgE molecules bound to FcεRI receptors on mast cells and basophils” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
IgE cross-linking on effector cells as the classic mechanism
“IgE-mediated anaphylaxis is considered the classic and most frequent mechanism. In this type, anaphylaxis is triggered by the interaction of an allergen (usually a protein) interacting with the allergen-specific IgE/high-affinity receptor (FcεRI) complex expressed on effector cells, predominantly mast cells and basophils.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preformed and newly synthesized mediators released on degranulation
“Degranulation results in the release of preformed mediators (histamine, heparin, tryptase, chymase, carboxypeptidase, cathepsin G and tumor necrosis factor alpha (TNF-α), and of de novo synthesized ones such as lipid mediators (cysteinyl leukotrienes), platelet activating factor (PAF), cytokines and growth factors such as vascular endothelial growth factor (VEGF).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Histamine actions at H1 and H2 receptors
“Experimental intravenous infusion of histamine in healthy volunteers can reproduce many of the symptoms and signs of anaphylaxis: flushing, headache, wheezing and transient hemodynamic changes such as systemic hypotension and tachycardia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Histamine binding to H1 receptor causes increased vascular permeability, bronchospasm, and GI contraction. Histamine binding to H2 receptor leads to flushing, glandular secretion, and cardiac contraction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanism of vasodilation, capillary leak, hypotension, and airway edema
“Recent data suggest that mast cell-derived histamine and PAF can activate nitric oxide production from endothelium and set into motion a signaling cascade that leads to dilatation of blood vessels and dysfunction of the endothelial barrier. The latter, characterized by the opening of adherens junctions, leads to increased capillary permeability and fluid extravasation. These changes contribute to airway edema, hypovolemia, and distributive shock, with potentially fatal consequences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Platelet-activating factor and reaction severity
“The platelet activating factor is the most potent mast cell mediator identified to date and is associated with decreased cardiac output, vascular hyperpermeability, smooth muscle contraction, hypovolemia, and cardiac collapse” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tryptase as a mast cell mediator and biomarker
Non-IgE-mediated and non-immunologic pathways
“The most relevant non-IgE-mediated immunologic mechanisms may involve the activation of pathways such as the complement system (anaphylatoxins, C3a, and C5a),35 the contact and coagulation system activation,36, 37, 38 or immunoglobulin G (IgG)-mediated anaphylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mast cells may be activated through receptors such as Mas-related G-protein coupled receptor member X2 (MRGPRX2) by certain drugs such as neuromuscular blocking agents and fluoroquinolones.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
How epinephrine reverses the physiology of anaphylaxis
“In anaphylaxis, effector cell mediators drive vasodilation, capillary leak and bronchospasm, which are responsible for the main clinical features” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adrenaline's alpha‐adrenergic stimulation of vascular smooth muscle and endothelial cells mediates potent vasoconstriction, mitigating against vasodilation, further capillary leak and hypotension. Beta‐1‐adrenergic stimulation has inotropic and chronotropic effects on the heart, increasing myocardial contractility and heart rate. Beta‐2‐adrenergic stimulation produces bronchodilation, counteracting the bronchospasm and wheeze seen in anaphylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Anaphylaxis as a clinical diagnosis without a confirmatory test
“Anaphylaxis is a clinical diagnosis that lacks a definitive test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is no gold-standard diagnostic test for anaphylaxis. Tryptase may be helpful to obtain, depending on the clinical scenario, for later supporting the diagnosis. Until better diagnostic tests are developed, anaphylaxis remains a clinical diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NIAID and FAAN clinical criteria: structure and organ system requirements
“In practice, clinicians rely on clinical criteria to assess the likelihood of anaphylaxis; however, these criteria are not perfectly sensitive or specific.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first applies to reactions without a likely or known trigger, the second to patients with likely allergen exposure, and the third to those with known allergen exposures. The first and second criteria require multisystem involvement, whereas the third accounts for the uncommon situation where a patient develops isolated hypotension after known allergen exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Test characteristics of the NIAID and FAAN criteria
“In the retrospective ED-based study (n =214), the test characteristics of the criteria were: sensitivity, 96.7% (95% CI, 88.8% to 99.1%); specificity, 82.4% (95% CI, 75.5% to 87.6%); positive predictive value, 68.6% (95% CI, 58.2% to 77.4%); negative predictive value, 98.4% (95% CI, 94.5% to 99.6%); positive likelihood ratio, 5.48; and negative likelihood ratio, 0.04.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, for the prospective ED study (n = 174), the test characteristics were: sensitivity, 95.1% (85.4%–98.7%); specificity, 70.8% (61.4%–78.8%); positive predictive value, 63.7% (52.9%–73.4%); negative predictive value, 96.4% (89.1%–99.1%); positive likelihood ratio, 3.26; and negative likelihood ratio, 0.07.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misapplication of the diagnostic criteria in clinical care
“The NIAID/FAAN criteria have been misused in clinical care as strict diagnostic criteria, leading clinicians to believe they can only administer epinephrine if a patient meets these criteria. In reality, they are meant to support clinical decision-making, and the decision to give epinephrine should be made independently of whether the criteria are met.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amended World Allergy Organization criteria
“Furthermore, the WAO Anaphylaxis Committee has proposed to amend the current NIAID/FAAN criteria, as shown in Table 2. The aim is to simplify the existing criteria, by combining the first 2 NIAID/FAAN criteria and modifying the third” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Typical skin symptoms AND significant symptoms from at least 1 other organ system; OR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exposure to a known or probable allergen for that patient, with respiratory and/or cardiovascular compromise.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GA2LEN consensus criteria and clinical support tool
“The clinical support tool incorporates a) new clinical criteria to help determine the likelihood that patients are having anaphylaxis, b) intramuscular epinephrine indications and dosing, and c) common findings from the anaphylaxis organ systems.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We propose that the anaphylaxis definition and clinical support tool should replace prior definitions and clinical criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum tryptase kinetics and interpretation
“During acute anaphylaxis, serum tryptase levels are increased from 15 min to 3 h or even longer, after the onset; levels peak between 1 and 2 h after the onset with 36–40% remaining <11.4 μg/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although elevated levels support a diagnosis of anaphylaxis, normal levels do not exclude anaphylaxis having occurred” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum tryptase threshold after suspected food-induced anaphylaxis
“The results of a serum tryptase test obtained 90 minutes to 4 hours after a suspected food-induced anaphylaxis event that show an increase by at least 1.2 times the patient’s baseline value plus 2 ng/mL is highly suggestive of mast cell degranulation and can assist allergy specialists in confirming the diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in which serum tryptase levels were measured before and during an oral food challenge to induce anaphylaxis, serum tryptase levels increased above baseline in 100 of 160 cases and increased above the upper limit of normal (11.4 ng/mL) in 4 out of 160 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Specific IgE serology and skin prick testing
“Allergic sensitization to suspected foods can be assessed by measuring food-specific serum IgE levels or performing skin prick testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given imprecise, variable predictive values, both skin prick testing and allergen-specific IgE, whether for single foods or in multifood panels, have limited utility as screening tools for food-protein allergies when interpreted without a history of allergic symptoms to a specific suspected food.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral food challenge as the reference standard
“The reference standard for the diagnosis of IgE-mediated food allergy is the oral food challenge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In practice, oral food challenges require significant time and clinical resources and inherently incur the risk of inducing allergic reactions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recognition difficulty in infants and young children
“Likewise, recognition of anaphylaxis may be especially challenging for noncommunicative patients including infants and young children who may present with nonspecific symptoms that overlap with normal infant behavior (eg, fussiness, drooling, spitting up).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Practice parameter recommendations on applying the diagnostic criteria
Clinical presentation - signs and symptoms
Multisystem involvement and reactions without skin signs
“Anaphylaxis usually occurs with multisystem involvement but can present with isolated cardiovascular or respiratory compromise. Skin/mucosa signs may be absent in up to 20% of presentations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cutaneous and mucosal symptoms
“Cutaneous symptoms (angioedema, flush, generalized erythema, generalized itching, generalized urticaria) were found in 294 patients (76.96%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Finding | Adult anaphylaxis emergency department visits (n = 1,422) |
|---|---|
| Any mucocutaneous symptom | “1392 (97.9%)”View highlighted excerpt for this quote |
| Flushing | “613 (43.1%)”View highlighted excerpt for this quote |
| Pruritus | “675 (47.5%)”View highlighted excerpt for this quote |
| Diffuse urticaria | “570 (40.1%)”View highlighted excerpt for this quote |
| Throat tightness | “780 (54.9%)”View highlighted excerpt for this quote |
| Angioedema | “824 (57.9%)”View highlighted excerpt for this quote |
Respiratory symptoms
“Respiratory symptoms (apnoea, dyspnoea, stridor) were found in 258 patients (67.54%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Finding | Adult anaphylaxis emergency department visits (n = 1,422) |
|---|---|
| Any respiratory symptom | “1196 (84.1%)”View highlighted excerpt for this quote |
| Cough | “251 (17.7%)”View highlighted excerpt for this quote |
| Voice change | “339 (23.8%)”View highlighted excerpt for this quote |
| Dyspnea | “987 (69.4%)”View highlighted excerpt for this quote |
| Wheezing | “375 (26.4%)”View highlighted excerpt for this quote |
| Hypoxemia | “87 (6.1%)”View highlighted excerpt for this quote |
Cardiovascular symptoms
“Cardiovascular symptoms (loss of consciousness, drop in blood pressure, collapse, cardiac arrest, dizziness, tachycardia, disorientation) were found in 279 patients (73.04%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Finding | Adult anaphylaxis emergency department visits (n = 1,422) |
|---|---|
| Any cardiovascular symptom | “764 (53.7%)”View highlighted excerpt for this quote |
| Hypotension | “185 (13.0%)”View highlighted excerpt for this quote |
| Presyncope | “517 (36.4%)”View highlighted excerpt for this quote |
| Syncope | “117 (8.2%)”View highlighted excerpt for this quote |
| Incontinence | “34 (2.4%)”View highlighted excerpt for this quote |
Gastrointestinal symptoms
“Gastrointestinal symptoms (abdominal pain, diarrhoea, nausea, vomiting, incontinence) were found in 111 patients (29%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Finding | Adult anaphylaxis emergency department visits (n = 1,422) |
|---|---|
| Any gastrointestinal symptom | “644 (45.3%)”View highlighted excerpt for this quote |
| Emesis | “206 (14.5%)”View highlighted excerpt for this quote |
| Nausea | “510 (35.9%)”View highlighted excerpt for this quote |
| Abdominal cramp | “229 (16.1%)”View highlighted excerpt for this quote |
| Diarrhea | “109 (7.7%)”View highlighted excerpt for this quote |
Neurological symptoms
“Nausea, vomiting, diarrhea, scrotal edema, uterine cramps, vaginal bleeding, urinary incontinence, dizziness, seizures, confusion, and syncope may also be seen” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Category | Quoted findings |
|---|---|
| Neurological symptoms | “confusion, drowsy, headache”View highlighted excerpt for this quote |
| Neurological signs | “unexplained change in mental status, lethargy, somnolence, seizure”View highlighted excerpt for this quote |
| Neurological findings in infants | “hypotonia, persistent and unexplained irritability, inconsolability, crying, or decreased activity”View highlighted excerpt for this quote |
| Findings not assigned to one organ system | “lower back pain in women due to uterine cramping, sense of impending doom, metallic taste, anxiety”View highlighted excerpt for this quote |
Signs and symptoms specific to infants and young children
“Infants with anaphylaxis may have distinct signs such as a hoarse cry (laryngeal involvement), repetitive lip licking (mucosal involvement), or abrupt non-specific behavioral changes (e.g., irritability, persistent crying).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Onset and progression of reactions
“Reactions occur along a severity spectrum including life-threatening anaphylaxis, which is characterized by airway, breathing, and/or cardiovascular (ABC) compromise. Anaphylaxis is dynamic; reactions may initially appear mild and then become severe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Recurrence of anaphylaxis in a population-based cohort followed for 10 years
“Eight percent of the patients experienced anaphylaxis recurrence within 10 years, (recurrence rate of 2.6 per 100 person-years) with most patients having the first recurrence within four years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 46 patients who experienced one recurrence, three patients who experienced two, and one patient who experienced eight during the time period under study, for a total of 60 recurrences observed during 2290 patient-years of follow-up, resulting in a recurrence rate of 2.6 per 100 person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who experienced recurrent reactions typically experienced the recurrence in a relatively short time period, as the median time between the index and recurrent anaphylaxis was about seven months, with an interquartile range between 1 month and 4 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early emergency department revisits after pediatric anaphylaxis
“The median hospitalization rate was 3.5% (IQR 2.2, 6.0) and the 3-day ED revisit rate was 0.6% (IQR 0.4, 0.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 6 fatalities reported during the study period and 0.6 % (IQR 0.4, 0.9) of patients discharged from the ED during the index encounter had a 3-day ED revisit for anaphylaxis of which 11.4% (n=31) were hospitalized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Repeat emergency department treatment among individuals with food allergy
“More generally, recent US population-weighted survey data indicate that approximately 1 in 10 convincingly food-allergic individuals report receiving treatment for a food-allergic reaction in the emergency department within the past 12 months. Over 1 in 3 report that they have received food allergy treatment in the emergency department at some point in their lifetime.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Permanent neurological disability after near-fatal anaphylaxis
“The most devastating reactions result in death, or near-fatal episodes resulting in permanent neurological disability from hypoxic ischaemic encephalopathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“277 case studies and 14 case series were identified reporting 896 deaths and 28 disabilities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurological outcome after out-of-hospital cardiac arrest caused by anaphylaxis
Persistence and resolution of food allergy during childhood
“Allergies to peanuts, tree nuts, and seafood tend to persist, whereas those to cow’s milk, hen’s eggs, wheat, and soy are typically outgrown during the preschool years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From a relatively large-scale retrospective analysis of children with cow’s milk allergy in the United States with a median follow-up duration of 54 months, the resolution rates of cow’s milk allergy were 19% by 4 years, 42% by 8 years, 64% by 12 years, and 79% by 16 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adult-onset food allergy and severe reaction history among United States adults
“Among food-allergic adults, 51.1% (95% CI, 49.3%-52.9%) experienced a severe food allergy reaction, 45.3% (95% CI, 43.6%-47.1%) were allergic to multiple foods, and 48.0% (95% CI, 46.2%-49.7%) developed food allergies as an adult.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Type I allergic reactions including anaphylaxis
Humanistic burden and health-related quality of life
Population-level food allergy quality-of-life impairment among United States adults measured with the Food Allergy Independent Measure
“The overall estimated mean FAIM score was 2.87 (95% confidence interval: 2.83-2.90).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The population-level psychosocial burden of adults with FA is substantial, broadly distributed, and differs by demographic and allergic disease characteristics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical markers associated with greater quality-of-life impairment
“Reporting a current epinephrine autoinjector (EAI) prescription, severe allergic reaction history, history of EAI use, FA-related emergency department visits, or more FAs were also associated with significantly higher FAIM scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver-proxy psychosocial burden among United States children with food allergy
“The overall estimated mean caregiver-proxy FAIM scores for the US pediatric population were 2.79 (SE = 0.03) for reported FA, 2.96 (SE = 0.04) for convincing FA, and 3.21 (SE = 0.05) for physician-confirmed, convincing FA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While heterogenous to a degree, the psychosocial burden of children with FA was substantial irrespective of sociodemographic and clinical characteristics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver anxiety, health utility, and quality-of-life decrement in peanut allergy
“Male and female caregivers reported mean levels of anxiety significantly higher than United Kingdom population norms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The utility decrement was largely driven by the EQ-5D anxiety and depression domain: 44% of caregivers reported being at least slightly anxious or depressed, compared with those reporting at least slight problems with self-care (7%), mobility (9%), usual activities (17%), and pain or discomfort (19%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health utilities derived from food allergy specific quality-of-life instruments
“However, traditional HRQoL instruments lack the sensitivity to generate health utilities that capture the impact that food allergies, such as peanut allergies, may have on children’s mental health and daily activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The DCE disutilities were highest for severe food-related anxiety, emotional distress, and social limitations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean health utility for the actual EQ-5D-3L responses was 0.8431 (SD: 0.202, range: 0.193 to 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Social restriction and reliance on epinephrine auto-injectors in daily management
“Previous research describes how the stress of daily food allergy management compounded by the dearth of effective treatment options impacts family relationships and often limits social activities, ultimately contributing to impaired food allergy-related quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, among these same food-allergic individuals, 1 in 5 report having treated a food-allergic reaction with an epinephrine auto-injector with the highest rates of epinephrine auto-injector (EAI) use reported among food-allergic adolescents and young adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reported epinephrine auto-injector carriage rates and device-related concerns
“Despite this, studies have revealed that only about half of patients regularly carry an unexpired EAI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These anticipated reactions may be layered on top of other preexisting worries among patients with severe allergic reactions and their caregivers about when to use the EAI, potential side effects, needle phobias, and the force required to inject the drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barriers to AAI carriage were believed to be inconvenience of the size and difficulty of use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some were embarrassed of their AAIs and less likely to carry them because of shame, fear of being seen as different or irritation at having to explain themselves.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Total annual economic burden of food allergy in the United States
“In a 2013 study by Gupta et al, the annual economic cost of food allergy was estimated to be $24.8 billion, roughly $4,184 per year per child.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual direct medical costs including hospitalizations, clinician visits, and emergency department visits were $4.3 billion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct medical cost components from national healthcare database analyses
“Among US studies, a retrospective national US government healthcare database analysis of the annual direct costs of food allergy, including PA, over the years 2006 and 2007 estimated that total annual medical costs were $225 million (2007 US dollars), with office visits accounting for just over half of the cost; the rest of the cost was split among ED visits, inpatient and outpatient visits, ambulance transfers, and AAIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emergency department utilization for food-allergic reactions
“More generally, recent US population-weighted survey data indicate that approximately 1 in 10 convincingly food-allergic individuals report receiving treatment for a food-allergic reaction in the emergency department within the past 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trends in anaphylaxis emergency department visits and hospitalizations among United States older adults
“In 2006–2014, older adults experienced approximately 1,019,967 AAR-related ED visits; 173,844 AAR-related hospitalizations; 93,795 anaphylaxis-related ED visits; and 72,677 anaphylaxis-related hospitalizations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While AAR-related ED visit and hospitalization rates remained stable (P-trends=0.28 and 0.16, respectively), anaphylaxis-related ED visit and hospitalization rates significantly increased over time (37 visits per 100,000 population in 2006 to 51 in 2014, P-trend<0.001; 13 hospitalizations per 100,000 population in 2006 to 23 in 2014, P-trend<0.001), especially hospitalization rates for drug-related anaphylaxis (47 hospitalizations per 100,000 population in 2006 to 85 in 2014, P-trend<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inpatient severity and resource intensity of anaphylaxis admissions
“The mean length of stay for these hospitalizations was 6.4 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the total hospitalizations for anaphylaxis occurring between 2006–2014 among older adults, 28% of these visits involved intubation/ventilation, 3% involved cardiac arrest, and 5% of these visits resulted in inpatient death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epinephrine auto-injector acquisition cost and cost-effectiveness at prevailing United States prices
“The retail purchase price of autoinjectors is heterogeneous and often expensive even with insurance, in some instances reaching $690 per dual-pack package (2016 dollars), although retail device costs rarely exceeded $100 before 2010.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At a market cost of $715 per twin pack, the autoinjector incremental cost-effectiveness ratio was $2 742 697 per quality-adjusted life-year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The value-based price (incremental cost-effectiveness ratio, $100 000 per quality-adjusted life-year) for personal epinephrine based on 10-fold fatality risk difference was $24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Type I allergic reactions including anaphylaxis on families
Out-of-pocket and opportunity costs borne by families of children with food allergy
“Additionally, annual out-of-pocket costs related to food allergy were $5.5 billion and annual opportunity costs such as a caregiver leaving/changing jobs to care for their food allergic child was estimated to be $14.2 billion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“estimated annual lost labour productivity due to food allergy at $773 million, or $130 per child, associated with accompanying child to medical visits; $5.5 billion, or $931 per child, in annual out‐of‐pocket costs, including special diets/allergen‐free foods, changes in childcare, and changes in schools; and annual opportunity costs due to forgone labour market activities, at $14 billion, or $2399 per child.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver-reported direct medical costs and willingness to pay for treatment
“A survey of US caregivers of children with food allergy estimated direct medical costs of $4.3 billion annually (or $724 per child).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The caregivers also reported a willingness to pay $3504 per year per child for a safe and effective treatment that would allow the child to eat all foods; that total cost was estimated at $20.8 billion annually, a number similar to the total estimated indirect costs spent on children with food allergy ($20.5 billion). The total annual economic burden of food allergy was estimated to be $24.8 billion, which combined direct ($4.3 billion) and indirect costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver work absence, productivity loss, and career impact
“The overall mean number of days absent in the last 12 months and productivity impacted among caregivers currently in paid employment due to their child’s allergy were M = 1.6 (SD: 2.2) and M = 1.9 (SD: 3.6), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Absenteeism and productivity impacts increased with severity of child’s allergy, but not significantly (p > 0.05); however, career impact was significantly associated with increased severity (χ2 = 9.19, p = 0.01), with 43% of caregivers of children with severe peanut allergy reporting some career impact (e.g., having to change job or stop work or having restricted career choices).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Socioeconomic disparities in family-level food allergy costs
“A follow-up study identified significant socioeconomic disparities in the economic burden of childhood food allergy, with children in the lowest income stratum spending more than twice as much as those in other income groups on food allergy-related emergency department and hospitalization costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver job-related opportunity costs used in United States economic models
Economic impact of diagnostic testing
Limited specificity of skin prick and specific IgE testing and the resulting cost of false positive results
Direct charges and societal costs of an oral food challenge
“We also estimated the costs by utilizing Medicare physician fee schedule and device costs, and the amount (3 hours non-facility = $626.89 and 3 hours facility = $565.315) was close to the one obtained from fairhealthconsumer.org without including hospital outpatient fees (facility), which vary greatly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of confirmatory oral food challenges compared with food elimination
“The cost of OFC strategy was $8671 compared with $18 012 for the FE strategy for the length of the model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the OFC strategy, the total cost was $9341 less than FE and the increase in QALY after OFCs led to a 0.202 higher effectiveness in the OFC strategy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of drug allergy evaluation with skin testing and drug challenge
“The base case penicillin allergy evaluation costs $220 in 2016 United States dollars: $98 for personnel, $119 for consumables, and $3 for space.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In sensitivity analyses, lower cost estimates were achieved when only a drug challenge was performed (i.e., no skin test, $84) and a nurse practitioner provider was used ($170).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Range of costs across accounting methods for allergy evaluation
“The cost of penicillin allergy evaluation using the RCC method ranged from $225 (no E&M, 2-step challenge only) to $1,247 (two visits, penicillin skin test with ampicillin, 2-step challenge after skin testing).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of screening infants before peanut introduction
“Early peanut introduction reduces the risk of developing peanut allergy, especially in high-risk infants. Current US recommendations endorse screening but are not cost-effective relative to other international strategies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In deterministic SPT sensitivity analyses at base-case sensitivity and specificity rates, screening could be cost-effective at a high disutility rate (the negative effect of a food allergic reaction) (76-148 days of life traded) for an at-home vs in-clinic reaction in combination with high baseline peanut allergy prevalence among infants at high risk for peanut allergy and not yet exposed to peanuts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Intramuscular epinephrine auto-injectors
Guideline position: intramuscular epinephrine is first-line therapy
Guideline position: World Allergy Organization anaphylaxis guidance
“Intramuscular epinephrine (adrenaline) continues to be the first-line treatment for anaphylaxis. Nevertheless, its use remains suboptimal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose recommended for use by healthcare professionals is 0.01 mg/kg of body weight, to a maximum total dose of 0.5 mg, given by the intramuscular route” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dosing should be repeated every 5–15 min if symptoms are refractory to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendation to prescribe and carry self-injectable epinephrine
Timing of administration relative to symptom onset
Products available in the United States and device selection
Approved auto-injector dosing by body weight: EpiPen and EpiPen Jr
Auto-injector dose by weight band
| Patient weight | Quoted dosage |
|---|---|
| 30 kg or greater | “EpiPen 0.3 mg” |
| 15 kg to less than 30 kg | “EpiPen Jr 0.15 mg” |
Auto-injector dosing for infants and toddlers under 15 kg
Safety of intramuscular epinephrine delivered by auto-injector
Storage conditions for auto-injectors
Underuse of epinephrine in the community
“Only 21% of children and 7% of adults experiencing anaphylaxis in community settings receive epinephrine prior to hospital arrival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pre-hospital epinephrine is consistently associated with reduced biphasic risk and shorter emergency department stays, yet underuse persists in up to two-thirds of community events” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Autoinjector cost, limited public access, and training disparities fuel preventable deaths, particularly in low-resource settings” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reported barriers to auto-injector use
“Even when prescribed, the rates of AAI use remain low, ranging from 16% to 32%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common barriers to AAI use include patient reluctance due to the device’s design, fear of needles, pain at the injection site, worry about social embarrassment, and concerns about accidental needle injuries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Needle phobia as a factor against home management
Injection injuries with auto-injectors
Needle length and delivery depth
Cost and packaging constraints in the United States
Availability and affordability of auto-injectors internationally
Intranasal epinephrine
Approval of the first needle-free epinephrine product
Approved indication and dosing of epinephrine nasal spray
Nasal spray dose by weight band
| Patient weight | Quoted dosage |
|---|---|
| 30 kg or greater | “One spray of neffy 2 mg” |
| 15 kg to less than 30 kg | “One spray of neffy 1 mg” |
Labeled restriction in structural or anatomical nasal conditions
Storage and freezing constraints for the nasal spray
Pharmacokinetic and pharmacodynamic basis of the evidence for intranasal epinephrine
Comparison of intranasal epinephrine with injected epinephrine
“Notably, its nasal absorption is not affected by simultaneous upper respiratory infections, which supports its practical use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“New alternatives, such as intranasal and sublingual adrenaline devices, are being developed to improve access and minimize hesitation in treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absence of a clinical evidence base for noninjectable routes at the time of the 2023 update
Manual intramuscular epinephrine and prefilled syringes
Prefilled syringe without auto-injector function
Approved indication and dosing of the prefilled syringe
Manual administration where auto-injectors are unavailable
Cost position of syringes and ampules relative to auto-injectors
Adjunctive antihistamines and corticosteroids
Second-line status of antihistamines and glucocorticoids
“Second-line medications include beta2-adrenergic agonists, glucocorticoids, and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of H1-antihistamines has a limited role in treatment of anaphylaxis,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, antihistamines are now a third line treatment in some guidelines,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoids in acute management
“Glucocorticosteroids are commonly used in anaphylaxis, with the objective of preventing protracted symptoms, in particular in patients with asthmatic symptoms, and also to prevent biphasic reactions (eg, intravenous hydrocortisone, or methylprednisolone). However, there is increasing evidence that glucocorticosteroids may be of no benefit in the acute management of anaphylaxis, and may even be harmful; their routine use is becoming controversial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive agents do not substitute for epinephrine
“Corticosteroids may help reduce the risk of biphasic reactions, although supporting evidence is still limited. Intravenous methylprednisolone or hydrocortisone are commonly given for this purpose. Antihistamines are used as additional therapy but should never replace adrenaline as the first-line treatment. H1 antihistamines can help relieve urticaria and itching, while H2 antihistamines may offer extra benefit for gastrointestinal and cardiovascular symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive agents and biphasic reactions
“Observation following clinical stabilization is essential to detect symptom recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Evidence-based protocols support 4–6 hours of monitoring for low-risk uniphasic presentations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Practice pattern: adjunctive agents used in place of epinephrine
“Though there is no absolute contraindication to intramuscular epinephrine for the treatment of anaphylaxis, antihistamines and corticosteroids remain the most frequently drugs used to treat anaphylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trigger avoidance and allergen immunotherapy
Guideline recommendation on allergen avoidance and education
Burden associated with avoidance
“Vigilant avoidance prevents anaphylaxis recurrence from culprit allergens. However, it can be frustrating and associated with impaired quality of life, including bullying of food-allergic children, fear of anaphylaxis during airline travel, and anxiety over restrictions on exercise.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Venom immunotherapy and specialist referral
“Guidelines recommend that patients with anaphylaxis be referred to an allergy/immunology specialist for confirmation of the suspected trigger, advice on prevention and, where indicated, consideration for allergen immunotherapy (eg, insect venom).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral immunotherapy for food-induced anaphylaxis
“Allergen immunotherapy can help prevent food-induced anaphylaxis by raising the threshold for clinical reactions and encouraging immune tolerance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although oral immunotherapy (OIT) is not yet advised for routine practice because of concerns about its safety and standardization,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Beyond showing clinical benefit, OIT has been linked to a very low rate of severe adverse reactions that would require adrenaline use during home treatment (0.0-0.04%). Successfully completed OIT may lower the risk of anaphylaxis from accidental allergen exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunotherapy does not remove the need for rescue epinephrine
Limitations of current therapies
Summary: limitations of current therapies
Epinephrine is recommended as first-line treatment for anaphylaxis in every major guideline, but delivery of that treatment fails at several points. Community administration is uncommon: one review reports that 21% of children and 7% of adults experiencing anaphylaxis in community settings receive epinephrine before hospital arrival, and the same review describes underuse in up to 64% of pre-hospital events. Delay is consequential, because delayed administration of more than 60 minutes from onset is an independent predictor of biphasic recurrence, and in fatality case series most people who died of anaphylaxis did not receive timely epinephrine. Failure to carry a device contributes: the 2023 practice parameter update reports suboptimal rates of auto-injector prescription fills and refills, carriage, and use, and a 2025 review reports auto-injector use rates of 16% to 32% even among people who have been prescribed one, with device design, fear of needles, injection-site pain, social embarrassment, and concern about accidental needle injuries named as barriers. The World Allergy Organization guidance adds that limited availability of auto-injectors, and their affordability for some patients, remains a problem in many countries, and that needle phobia is listed among the considerations against managing an episode at home.
Device-related problems add to the gap. Reported auto-injector injuries include lacerations and embedded needles when a person moves during administration, when the device discharges off center, or when the needle bends after striking bone. Needle length is a design constraint in infants with low body mass, in women, and in adults with a body mass index above 25, and ultrasound-based work indicates that the risk of subcutaneous rather than intramuscular delivery is highest in women with obesity. Cost is a further constraint: a 2018 survey found that 97% of parents of children with food allergy in the United States felt financially burdened by the cost of auto-injectors, and the average wholesale price of two EpiPens rose from $113.27 in 2007 to $730.33 in 2016, with United States packaging sold only in two-unit packs. Storage adds a practical limit, since auto-injectors are labeled for 20°C to 25°C with excursions permitted only to 15°C to 30°C and must be protected from light, and the approved nasal spray does not deliver epinephrine while frozen. For intranasal epinephrine, the evidence base rests on pharmacokinetic and pharmacodynamic comparisons rather than on randomized efficacy trials in anaphylaxis, because ethical and practical constraints make such trials difficult; the label also states that subjects with structural or anatomical nasal conditions were not studied and advises considering another route for those patients. The 2023 practice parameter update states explicitly that it addresses only injectable epinephrine and that noninjectable routes had no clinical evidence base at the time it was written.
Place in treatment, anticipated use, and care setting
Summary: anticipated place of dibutepinephrine sublingual film in treatment
Dibutepinephrine sublingual film is an investigational rescue treatment for Type I allergic reactions including anaphylaxis, positioned in the same use setting as an epinephrine auto-injector rather than as a maintenance or preventive therapy. Because most anaphylaxis occurs outside medical settings, the relevant care settings are the community locations where guidelines already direct patients to carry epinephrine: home, school and childcare, restaurants, travel, and workplaces. The 2023 practice parameter update recommends that people at high risk always carry self-injectable epinephrine, and the World Allergy Organization guidance directs that epinephrine be given at the first sign of anaphylaxis and that patients be taught self-administration; a product that removes the needle and the device addresses carriage and hesitation rather than the underlying indication.
The manufacturer describes the product as similar in size to a postage stamp, weighing less than an ounce, beginning to dissolve on contact, and requiring no water or swallowing, with primary packaging thinner and smaller than an average credit card that can be carried in a pocket and is designed to withstand exposure to rain or sunlight. Aquestive states that it is preparing a focused, allergist-first launch, with medical affairs activity directed at the allergy community and partnerships with allergy-focused patient advocacy organizations, and describes the market opportunity as conversion from older autoinjector device technology. The company has not stated that the film would replace an auto-injector for a given patient; the FDA labeling that would define whether it substitutes for or supplements an auto-injector has not been issued, because the application received a Complete Response Letter dated January 30, 2026 and was resubmitted on September 17, 2026. A 2025 review of anaphylaxis management describes sublingual delivery as an alternative developed to address low auto-injector use rather than as a replacement for guideline-recommended intramuscular epinephrine.
Anticipated market conversion from injector devices
Independent description of sublingual delivery in the treatment landscape
“Various intranasal and sublingual delivery systems have been investigated to enhance patient compliance and improve outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, sublingual delivery is an encouraging alternative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to intramuscular adrenaline, Anaphylm reaches similar plasma epinephrine levels and has a comparable side effect profile, while achieving peak plasma concentration significantly faster.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-administration and caregiver administration in community settings
Heterogeneity of treatment effect
Children and adolescents: pharmacokinetic data limited to participants weighing more than 30 kg
Infants and toddlers: dose and device uncertainty below 15 kg
High body weight: route of delivery and bioavailability of injected epinephrine
Oral allergy syndrome and oropharyngeal involvement
“Pollen-food allergy syndrome (PFAS) is another important factor in food-induced anaphylaxis. Although PFAS usually causes mild symptoms limited to the mouth and throat, it can sometimes lead to severe systemic reactions, including anaphylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant beta-blockers: reduced responsiveness to epinephrine
“Some patients may not respond well to standard doses of adrenaline. Beta-blockers are the most common reason of adrenaline resistance, as they block beta-adrenergic receptors. In these cases, glucagon should be considered because it works independently of these receptors. ACE inhibitors, angiotensin receptor blockers, tricyclic antidepressants, preexisting cardiovascular disease, and older age can also decrease responsiveness to adrenaline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant beta-blockers and angiotensin-converting enzyme inhibitors: severity of reactions
Pregnancy: treatment should not be delayed
Older adults and cardiovascular comorbidity
Care management intervention strategies
Written anaphylaxis emergency action plans
“In addition, it is recommended that they always carry a personalized written anaphylaxis emergency action plan that illustrates how to recognize anaphylaxis symptoms (eg, tingling in the extremities, sense of heat, sense of dizziness/fainting, swollen lips-tongue-uvula, shortness of breath, wheeze, stridor, collapse) and instruct them to inject epinephrine rapidly, via the intramuscular route, in the mid-anterolateral thigh, holding the EAI in place for about 3–10 s and then to call for medical assistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the time of discharge from a health care setting, patients, at risk of another episode of anaphylaxis, should be prescribed and taught about self-administration of epinephrine (adrenaline), and have a written personalized anaphylaxis emergency action plan and medical identification method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient and caregiver education and device training
Stock epinephrine and staff training in schools and childcare centers
State laws governing stock epinephrine in schools
“All 50 states and DC allow undesignated epinephrine in schools to use for allergic or anaphylactic reactions. A key difference arises in whether states allow (N=37) or mandate (N=14) that schools stock epinephrine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This review of stock epinephrine laws and policies highlights the significant variation in state legislation despite widespread adoption. Only one-quarter of states mandate that schools have stock epinephrine available for emergency use, underscoring need for a more unified approach with consistent guidelines, comprehensive training, and possible funding for implementation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dosage form specified by school stock epinephrine laws
“In addition, most states (N=45) require auto-injectable epinephrine to be available at school. One state requires pre-filled syringes (Missouri). Five states do not specify the dispense method for stock epinephrine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-nine states indicate students can administer stock epinephrine themselves.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
School action plans and administration documentation
Stock epinephrine in other community settings
Immediate steps taken during an episode
“Therefore, when a patient has anaphylaxis it is important to follow the steps outlined (Fig. 4): remove exposure to the trigger if possible (eg, discontinue administration of drugs/therapeutic agents), assess airways, breathing, circulation, mental status, and skin, and simultaneously call emergency services, injecting epinephrine (adrenaline) intramuscularly into the vastus lateralis of the quadriceps (antero-lateral thigh), and positioning the patient according to his/her presenting features.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Referral pathway and follow-up after an episode
“Most cases of anaphylaxis are first seen by emergency doctors or general practitioners, but only 50% are referred to a specialist for further investigation and/or treatment. Provision of advice relating to trigger avoidance and emergency protocols, at the time of discharge from the emergency room, are practically nonexistent, according to the international survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One of the major concerns is the underuse of epinephrine self-infectors by patients who experience anaphylaxis recurrences, despite having the medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of devices prescribed and refill considerations
Other product development or post-marketing obligations required by the FDA
Studies required by the FDA in the Complete Response Letter
Manufacturing and comparability findings not questioned by the FDA
Pediatric trial agreed with the FDA before submission
Ongoing post-approval monitoring
Post-marketing commitments discussed during FDA review
Risk evaluation and mitigation strategy, registries, and post-marketing surveillance
No evidence found.
Expected outcomes of therapy
Summary: definition of a successful treated episode
Successful treatment of an anaphylactic episode is defined in the 2023 practice parameter update as a prompt, complete, and durable response to epinephrine: signs and symptoms that were present before administration resolve within minutes, do not recur, and no additional epinephrine or emergency medical services activation is required. Under that definition the measurable outcomes of therapy are resolution of the presenting signs and symptoms, avoidance of a second epinephrine dose, avoidance of emergency medical services activation and emergency department transfer, and absence of a biphasic recurrence. Across reported series, 7.7% of anaphylaxis cases of all ages and causes were treated with more than one dose of epinephrine, and a meta-analysis of 2890 adult participants with anaphylaxis found a median biphasic reaction rate of 6.5% with a range of 0.4% to 20%. Pre-hospital epinephrine is associated with lower odds of biphasic reaction and shorter emergency department stays, and delayed administration of more than 60 minutes from onset is an independent predictor of biphasic recurrence. Aquestive has not published an efficacy endpoint in treated anaphylaxis for dibutepinephrine sublingual film; the development program used pharmacokinetic and pharmacodynamic comparisons with intramuscular epinephrine, and the company states that the resubmitted application addresses the human factors and confirmatory pharmacokinetic items raised in the Complete Response Letter.
Symptom resolution that permits observation at home
Frequency of a required second dose of epinephrine
Biphasic reaction rates and timing
Early epinephrine and avoided emergency care
“Reported incidence ranges from 4% to 20%, with large emergency department cohorts estimating the rate at approximately 7–16%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Delayed epinephrine (>60 min), drug or idiopathic triggers, and angioedema are the strongest independent predictors of biphasic recurrence” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pre-hospital epinephrine is consistently associated with reduced biphasic risk and shorter emergency department stays, yet underuse persists in up to two-thirds of community events” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote